ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Krista Davis sold 1,730 shares of the business's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $77.99, for a total transaction of $134,922.70. Following the sale, the senior vice president directly owned 49,263 shares of the company's stock, valued at approximately $3,842,021.37. The trade was a 3.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Krista Davis also recently made the following trade(s):
- On Thursday, February 19th, Krista Davis sold 2,084 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $77.53, for a total transaction of $161,572.52.
- On Thursday, December 18th, Krista Davis sold 1,622 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $82.40, for a total value of $133,652.80.
ANI Pharmaceuticals Stock Performance
Shares of ANI Pharmaceuticals stock opened at $75.10 on Tuesday. ANI Pharmaceuticals, Inc. has a 52 week low of $54.10 and a 52 week high of $99.50. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The business has a 50 day moving average price of $80.69 and a 200-day moving average price of $86.64. The company has a market cap of $1.69 billion, a PE ratio of 46.07 and a beta of 0.50.
Institutional Trading of ANI Pharmaceuticals
Large investors have recently added to or reduced their stakes in the stock. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals in the first quarter worth about $28,000. Hantz Financial Services Inc. increased its stake in shares of ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company's stock worth $32,000 after purchasing an additional 237 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of ANI Pharmaceuticals by 4,636.4% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company's stock worth $34,000 after purchasing an additional 510 shares during the period. Newbridge Financial Services Group Inc. lifted its stake in ANI Pharmaceuticals by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company's stock valued at $39,000 after purchasing an additional 400 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in ANI Pharmaceuticals in the fourth quarter valued at approximately $48,000. Hedge funds and other institutional investors own 76.05% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on the company. Weiss Ratings restated a "hold (c+)" rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Guggenheim raised their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a "buy" rating in a research report on Friday, January 16th. Zacks Research downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, January 6th. Finally, Barclays initiated coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an "overweight" rating and a $100.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $103.43.
Check Out Our Latest Stock Report on ANI Pharmaceuticals
ANI Pharmaceuticals Company Profile
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
